Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapydan versus EMLA for venipuncture pain prevention in children
NL-OMON35993Phase 4Active, not recruiting
- Sponsor
- Isala
- Start
- Mar 2011
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial comparing Rapydan arm with EMLA arm (2 arms). Primary endpoint: Pain score on faces pain scale. Started Mar 2011; status: active, not recruiting.
02
Drugs
S-Cainelidocaine + prilocaine
Beyond the preview
Go deeper on NL-OMON35993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35993.